Basilea Secures $6M BARDA Funding for Novel Antibiotic Development
Event summary
- Basilea received $6M from BARDA to advance ceftibuten-ledaborbactam etzadroxil for cUTIs.
- The funding supports Phase 3 clinical study preparations for the oral antibiotic.
- Total potential BARDA funding reaches $147M upon milestone completion.
- Ceftibuten-ledaborbactam targets multidrug-resistant Enterobacterales infections.
- The drug has FDA QIDP and Fast Track designations for cUTI and uncomplicated UTIs.
The big picture
Basilea's funding from BARDA underscores the critical need for new oral antibiotics to combat multidrug-resistant urinary tract infections. The $147M potential funding highlights the strategic importance of developing treatments for antibiotic-resistant pathogens, a growing global health challenge. This investment positions Basilea as a key player in the race to address the rising threat of resistant bacterial infections.
What we're watching
- Clinical Progress
- Whether Basilea can successfully complete Phase 3 studies to validate ceftibuten-ledaborbactam's efficacy against multidrug-resistant infections.
- Regulatory Pathway
- The pace at which FDA approval could be achieved given the Fast Track and QIDP designations.
- Funding Utilization
- How Basilea allocates the $6M and subsequent BARDA funding to maximize development efficiency.
Related topics